The Impact of Epithelial-Mesenchymal Transition and Metformin on Pancreatic Cancer Chemoresistance: A Pathway towards Individualized Therapy
- PMID: 35454306
- PMCID: PMC9032206
- DOI: 10.3390/medicina58040467
The Impact of Epithelial-Mesenchymal Transition and Metformin on Pancreatic Cancer Chemoresistance: A Pathway towards Individualized Therapy
Abstract
Globally, pancreatic ductal adenocarcinoma remains among the most aggressive forms of neoplastic diseases, having a dismal prognostic outcome. Recent findings elucidated that epithelial-mesenchymal transition (EMT) can play an important role in pancreatic tumorigenic processes, as it contributes to the manifestation of malignant proliferative masses, which impede adequate drug delivery. An organized literature search with PubMed, Scopus, Microsoft Academic and the Cochrane library was performed for articles published in English from 2011 to 2021 to review and summarize the latest updates and knowledge on the current understanding of EMT and its implications for tumorigenesis and chemoresistance. Furthermore, in the present paper, we investigate the recent findings on metformin as a possible neoadjuvant chemotherapy agent, which affects EMT progression and potentially provides superior oncological outcomes for PDAC patients. Our main conclusions indicate that selectively suppressing EMT in pancreatic cancer cells has a promising therapeutic utility by selectively targeting the chemotherapy-resistant sub-population of cancer stem cells, inhibiting tumor growth via EMT pathways and thereby improving remission in PDAC patients. Moreover, given that TGF-β1-driven EMT generates the migration of tumor-initiating cells by directly linking the acquisition of abnormal cellular motility with the maintenance of tumor initiating potency, the chemoprevention of TGF-β1-induced EMT may have promising clinical applications in the therapeutic management of PDAC outcomes.
Keywords: cancer stem cells; chemotherapy; epithelial–mesenchymal transition; metformin; pancreatic ductal carcinoma.
Conflict of interest statement
All authors participated in the (a) conception and design, or analysis and interpretation of the data; (b) drafting the article or revising it critically for important intellectual content; and (c) approval of the final version. This manuscript has not been submitted to, nor is under review at another journal or other publishing venue. The authors have no affiliation with any organization with a direct or indirect financial interest in the subject matter discussed in the manuscript.
Figures


Similar articles
-
Caffeic Acid and Metformin Inhibit Invasive Phenotype Induced by TGF-β1 in C-4I and HTB-35/SiHa Human Cervical Squamous Carcinoma Cells by Acting on Different Molecular Targets.Int J Mol Sci. 2018 Jan 16;19(1):266. doi: 10.3390/ijms19010266. Int J Mol Sci. 2018. PMID: 29337896 Free PMC article.
-
Metformin Inhibits TGF-β1-Induced Epithelial-to-Mesenchymal Transition via PKM2 Relative-mTOR/p70s6k Signaling Pathway in Cervical Carcinoma Cells.Int J Mol Sci. 2016 Nov 30;17(12):2000. doi: 10.3390/ijms17122000. Int J Mol Sci. 2016. PMID: 27916907 Free PMC article.
-
Deciphering epithelial-to-mesenchymal transition in pancreatic cancer.Adv Cancer Res. 2023;159:37-73. doi: 10.1016/bs.acr.2023.02.008. Epub 2023 Mar 23. Adv Cancer Res. 2023. PMID: 37268401 Review.
-
Metformin suppresses the invasive ability of pancreatic cancer cells by blocking autocrine TGF‑β1 signaling.Oncol Rep. 2018 Sep;40(3):1495-1502. doi: 10.3892/or.2018.6518. Epub 2018 Jun 22. Oncol Rep. 2018. PMID: 29956804
-
Epithelial-Mesenchymal Transition in Pancreatic Cancer: A Review.Biomed Res Int. 2017;2017:2646148. doi: 10.1155/2017/2646148. Epub 2017 Dec 12. Biomed Res Int. 2017. PMID: 29379795 Free PMC article. Review.
Cited by
-
Trends in metabolic signaling pathways of tumor drug resistance: A scientometric analysis.Front Oncol. 2022 Oct 25;12:981406. doi: 10.3389/fonc.2022.981406. eCollection 2022. Front Oncol. 2022. PMID: 36387132 Free PMC article.
-
The lncRNA UCA1 Enhances Pancreatic Cancer EMT by Regulating miR-708-5p and miR-135b-5p: A Bioinformatics Approach.Iran J Public Health. 2024 Jul;53(7):1659-1669. doi: 10.18502/ijph.v53i7.16060. Iran J Public Health. 2024. PMID: 39086404 Free PMC article.
-
[Research Progress on the Combination Therapy of EGFR-TKIs and Metformin in Acquired Resistance to EGFR-TKIs in Non-small Cell Lung Cancer].Zhongguo Fei Ai Za Zhi. 2023 Nov 20;26(11):874-880. doi: 10.3779/j.issn.1009-3419.2023.106.22. Zhongguo Fei Ai Za Zhi. 2023. PMID: 38061889 Free PMC article. Chinese.
-
Nano-drug delivery system for pancreatic cancer: A visualization and bibliometric analysis.Front Pharmacol. 2022 Oct 18;13:1025618. doi: 10.3389/fphar.2022.1025618. eCollection 2022. Front Pharmacol. 2022. PMID: 36330100 Free PMC article.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical